BPC-157 and Wound Healing: What the Published Research Says

Published August 22, 2026 · Artemis Labs

BPC-157 wound healing research — answer capsule: BPC-157 is a 15-amino-acid peptide studied for how wounds close and repair in animal and cell models. A 2015 study reported faster closing of chemical burn wounds in animals given BPC-157, and in lab dishes the peptide was linked to skin cells multiplying, moving toward the wound edge, and forming new blood-vessel structures (Huang 2015). A 2016 rat study reported improved repair of a rectovaginal fistula, an abnormal tunnel between the rectum and the vagina (Baric 2016). Researchers connect these results to raised levels of VEGF, EGF, and HGF — natural body signals that tell tissue to grow new blood vessels, new surface cells, and repaired structures. All of this evidence comes from animals and lab cultures; no published human trial has tested whether BPC-157 heals wounds in people.

Key findings

• In a preclinical alkali-burn model — a chemical burn caused by a strong base, such as lye — animals treated with BPC-157 showed improved wound healing compared with untreated animals (Huang 2015, DOI: 10.2147/DDDT.S82030).
• The same 2015 paper ran cell-culture experiments and reported three separate lab readouts: cells multiplied more, migrated toward a scratch “wound” faster, and formed more new blood-vessel-like tubes (Huang 2015).
• In rats with a surgically created rectovaginal fistula, BPC-157 treatment was linked to better closure of the abnormal channel (Baric 2016, DOI: 10.1016/j.lfs.2016.02.029).
• A 2018 review compared BPC-157 with standard angiogenic growth factors — the reference proteins scientists use to trigger new blood-vessel growth in experiments (Seiwerth 2018, DOI: 10.2174/1381612824666180712110447).

What is BPC-157?

BPC-157 is a peptide — a short chain of amino acids, the building blocks of proteins. It is 15 amino acids long, and its sequence is a partial copy of a protein found in human stomach juice. Because of an unusual triple-proline section in its backbone, it resists being broken down by digestive enzymes. Published work reports it stays intact in human gastric juice for more than 24 hours, which is rare for a small unmodified peptide.

Wound healing is one of the most-studied questions in the BPC-157 literature. Labs have asked a simple thing: when tissue is damaged, do animals or cells exposed to this peptide repair the damage differently than untreated controls? The BPC-157 research peptide sold for laboratory use is the same 15-amino-acid sequence these studies describe.

What did the 2015 burn wound study find?

The most-cited wound paper is Huang 2015. It is valuable because it did not rely on one measurement. It combined a live-animal experiment with three different cell-culture experiments, so each result could be checked against the others.

The animal part used an alkali burn. An alkali is a strong base — the chemical family that includes lye — and it produces a deep, slow-healing wound. Animals given BPC-157 showed improved healing of these burn wounds compared with untreated animals (Huang 2015, DOI: 10.2147/DDDT.S82030).

The lab-dish part measured three things, each worth explaining plainly:

• Proliferation — did cells multiply? A wound cannot close without new cells to fill it. The study reported more cell growth with BPC-157.
• Migration — did cells move? Skin cells have to travel across a wound bed to seal it. In a standard “scratch test,” where researchers scrape a gap in a sheet of cells and watch it refill, BPC-157-exposed cells closed the gap faster.
• Angiogenesis — did new blood-vessel structures form? Fresh tissue needs a blood supply, and this readout counts the tube-like structures that vessel-lining cells build in a dish. The study reported more tube formation with BPC-157.

Together, those readouts sketch a picture of how a wound might close: more cells, moving faster, with a growing blood supply. The blood-vessel piece is a research area of its own — our page on BPC-157 blood vessel research covers it in more depth.

What happened in the fistula repair study?

A fistula is an abnormal tunnel that forms between two body parts that should not be connected. Baric 2016 studied a rectovaginal fistula in rats — a channel between the rectum and the vagina, created surgically for the experiment. Fistulas are a hard test for any repair studied in a lab, because the tunnel involves two different tissue types and constant exposure to gut contents.

In that model, rats given BPC-157 showed better repair of the fistula than untreated rats (Baric 2016, DOI: 10.1016/j.lfs.2016.02.029). The authors tied the result to the same growth-factor signals seen in the burn work. For wound researchers, the interest is that this was not a simple skin cut: it was a complex, two-surface defect, and the peptide was still associated with improved closure in the treated animals.

How does BPC-157 compare with known growth factors?

Growth factors are the body’s own repair messengers — proteins that tell cells to divide, move, or build new structures. Scientists use certain well-characterized ones as benchmarks when they study anything that might affect blood-vessel growth. Seiwerth 2018 reviewed BPC-157 side by side with these standard angiogenic growth factors, placing the peptide’s reported effects in the context of the reference molecules the field already understands.

Three growth factors come up again and again in the BPC-157 wound literature, and the burn, fistula, and eye models all reported raised levels of them after treatment (Huang 2015; Baric 2016; Sikiric 2023):

• VEGF — the signal that tells the body to grow new blood vessels.
• EGF — the signal that tells skin and surface cells to grow and divide.
• HGF — a broad repair signal that tells damaged tissue to rebuild.

The working idea in these papers is that BPC-157 does not patch tissue by itself. Instead, the studies report that treated tissue produced more of its own repair signals. The eye findings behind that third citation are summarized on our BPC-157 eye research page.

One honest caveat belongs here. BPC-157 has no single defined receptor — no one docking site on cells that fully explains its reported effects — and no standard lab assay defines what a “positive” response looks like. Reported effect sizes also vary a good deal between models, doses, routes, and species. That makes the mechanism story a working hypothesis, not settled biology.

What the research does not show

No published Phase II or Phase III human trial has tested whether BPC-157 heals wounds — or anything else — in people. The only published human work is early pilot safety testing referenced in recent reviews (Mendias 2026), and safety testing does not measure whether a compound works. Every wound-healing finding on this page comes from animals or cells in a dish, and results in animal models often fail to repeat in humans. The mechanism picture is also unsettled: with no defined receptor and no agreed biomarker of activity, researchers cannot yet say precisely how the reported effects happen. BPC-157 is not an FDA-approved drug for any use.

Frequently asked questions

Has BPC-157 been shown to close wounds in humans?

No. All published wound-healing findings come from animal models and cell cultures. No human efficacy trial — a study testing whether it actually works in people — has been published for any use.

What kinds of wounds have been studied?

The two backbone studies used a chemical (alkali) burn in a live-animal model (Huang 2015) and a surgically created rectovaginal fistula in rats (Baric 2016). Cell-culture work in the 2015 paper also modeled wound closure in a dish.

What are VEGF, EGF, and HGF?

They are growth factors — natural signaling proteins the body uses to run repair. VEGF calls for new blood vessels, EGF tells surface cells to grow, and HGF is a broad rebuild signal. BPC-157 studies in burn, fistula, and eye models reported raised levels of all three after treatment.

How does BPC-157 fit among other repair-focused peptides?

It is one of several peptides studied in tissue-repair models, each with a different structure and mechanism profile. Our complete guide to recovery and tissue repair peptides compares the group side by side.

References

1. Huang et al. (2015). Alkali-burn wound healing in vivo; proliferation, migration, and angiogenesis readouts in vitro. DOI: 10.2147/DDDT.S82030
2. Baric et al. (2016). Rectovaginal fistula repair in a rat model. DOI: 10.1016/j.lfs.2016.02.029
3. Seiwerth et al. (2018). BPC-157 compared with standard angiogenic growth factors. DOI: 10.2174/1381612824666180712110447
4. Sikiric et al. (2023). Review of ocular-condition animal models, including growth-factor findings. DOI: 10.3390/ph16071052
5. Mendias CL, Awan TM. Sports Med. 2026. PMID 41966639

Methodology: This page draws exclusively on the verified BPC-157 research record compiled by Artemis Labs (citations last verified August 22, 2026); no facts beyond that record appear here.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.